Influenza & Respiratory

 

 

This event will tackle the latest issues affecting vaccines for respiratory diseases including influenza, TB, RSV and MERS to stimulate the industry to develop more effective vaccines. Ensure you use this event to make people aware of your expertise around key topics such as universal and seasonal flu, maternal immunization and pandemic preparedness.

 

2018 AGENDA

Influenza & Respiratory, Wednesday 4 April 2018

RSV Vaccines & Maternal Immunization

Dr Martin Moore
Influenza & Respiratory
09:40

Achieving an effective balance of attenuation and immunogenicity for RSV live attenuated vaccines (LAV)

·         Engineering RSV LAV strains with enhanced immunogenicity using a multi-faceted, rational mutagenesis approach

·         Enhancing expression of the pre-fusion conformation of the RSV fusion (F) protein

·         Using genetic mapping to identify residues that correlate with pre-fusion antigen maintenance and thermal stability of infectivity into LAV candidates

·         Candidates exhibiting elevated pre-fusion antigen levels, thermal stability, immunogenicity, and efficacy

10:40

Networking coffee break

Dr Gregory Glenn
Influenza & Respiratory
11:40

The RSV F Nanoparticle Vaccine for Infants via Maternal Immunization in Phase 3: Rationale and Update

Influenza & Respiratory
12:10

Virospot MN Assay methodology and research findings

Prof Louis Bont
Influenza & Respiratory
12:40

Landscape analysis of RSV vaccine development and future implications

Universal and Pandemic Influenza Vaccines

Dr Sean Tucker
Influenza & Respiratory
12:55

Comparisons between QIV and Vaxart’s oral vaccine for protection against influenza challenge in humans

1:10

Networking Lunch & Poster Session

Dr Brian Ward
Influenza & Respiratory
2:40

Characterization of the immune response induced by plant-made influenza vaccines

Immunogenicity of a plant-derived quadrivalent VLP vaccine in adults and the elderly

·         Phase 2 clinical results on QIV seasonal VLPs in healthy adults and elderly

·         Comparison of humoral and cell-mediated immune responses induced by VLPs

Andrew Catchpole
Influenza & Respiratory
3:10

Utilizing human challenge studies to accelerate the development of respiratory vaccines

Session title TBC

Influenza & Respiratory
3:55

Results of a PhIa study of a universal influenza vaccine in healthy adults

  • The promise of prevention: A novel universal vaccine virus Protection from drifted or mismatched flu strains
  • Breadth of protection in multiple age groups
4:10

Networking coffee break

Influenza & Respiratory
4:40

100 Years since 1918: Are we ready for the next pandemic?

Dr Giuseppe Ciaramella
Influenza & Respiratory
5:10

Clinical data from our pandemic influenza mRNA vaccines (H7N9 and H10N8)

Influenza & Respiratory
5:40

Maternal immunization on respiratory infections: Benefits to mother and child

6:10

Chair’s closing remarks and close of congress day 2

6:15

Networking Drinks & Party

last published: 12/Dec/17 18:15

Influenza & Respiratory, Thursday 5 April 2018

Influenza & Respiratory
09:00

Chair’s opening remarks

The Rise of AMR: Vaccine Development Against Bacterial Infections

Dr Rino Rappuoli
Influenza & Respiratory
09:10

Results on developing a new pertussis vaccine – Opportunities for maternal

·         The need for a new pertussis vaccine with longer lasting immunity

·         Challenges in making an effective pertussis vaccines: Cyclical by nature, waning immunity, asymptomatic carriers

Dr Alessandro Sette
Influenza & Respiratory
09:40

Immune profiling techniques to help develop a more effective pertussis vaccine

Influenza & Respiratory
10:10

The prevention and control of pneumococcal diseases

10:40

Networking coffee break

Dr Ann Ginsberg
Influenza & Respiratory
11:30

Recent progress in clinical TB vaccine development

Dr Simona Rondini
Influenza & Respiratory
12:00

Presenting early stage development of a vaccine to prevent the bacterial infections that exacerbate Chronic Obstructive Pulmonary Disease (COPD)

·         COPD is a very common, chronic, progressive, respiratory illness of adults, which can be triggered by bacterial infections

·         A vaccine to prevent these respiratory infections could modify the clinical progression of COPD, and improve quality of life

12:30

Networking Lunch & Poster Session

AFTERNOON PLENARY OF CONGRESS

last published: 12/Dec/17 18:15

 

DOWNLOAD DRAFT AGENDA

Get Involved At World Vaccine Congress Washington

 

To Sponsor Or Exhibit

 

Marc Rhys-Evans
marc.rhys-evans@terrapinn.com
+44 20 7827 5945

 

 

 

To Register

 

Tayyab Abbasi
tayyab.abbasi@terrapinn.com
+44 20 7092 1210

 

 

 

Press Relations

 

Karina Kusova
karina.kusova@terrapinn.com
+44 20 7092 1071

 

 

Error processing SSI file